- Home
- TCBX vs URGN Comparison
TCBX vs URGN Comparison
Compare TCBX & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBX
- URGN
- Stock Information
- Founded
- TCBX 2008
- URGN 2004
- Country
- TCBX United States
- URGN United States
- Employees
- TCBX N/A
- URGN N/A
- Industry
- TCBX Banks
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- TCBX Finance
- URGN Health Care
- Exchange
- TCBX Nasdaq
- URGN Nasdaq
- Market Cap
- TCBX 454.9M
- URGN 465.9M
- IPO Year
- TCBX 2021
- URGN 2017
- Fundamental
- Price
- TCBX $33.37
- URGN $11.06
- Analyst Decision
- TCBX Buy
- URGN Strong Buy
- Analyst Count
- TCBX 4
- URGN 6
- Target Price
- TCBX $37.25
- URGN $40.75
- AVG Volume (30 Days)
- TCBX 63.5K
- URGN 418.3K
- Earning Date
- TCBX 04-23-2025
- URGN 03-10-2025
- Dividend Yield
- TCBX N/A
- URGN N/A
- EPS Growth
- TCBX 40.59
- URGN N/A
- EPS
- TCBX 2.78
- URGN N/A
- Revenue
- TCBX $165,678,000.00
- URGN $90,398,000.00
- Revenue This Year
- TCBX $17.70
- URGN $43.60
- Revenue Next Year
- TCBX $6.73
- URGN $103.77
- P/E Ratio
- TCBX $11.93
- URGN N/A
- Revenue Growth
- TCBX 17.16
- URGN 9.29
- 52 Week Low
- TCBX $18.00
- URGN $9.03
- 52 Week High
- TCBX $39.45
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- TCBX 44.76
- URGN 50.86
- Support Level
- TCBX $31.73
- URGN $11.12
- Resistance Level
- TCBX $35.10
- URGN $11.91
- Average True Range (ATR)
- TCBX 1.18
- URGN 0.57
- MACD
- TCBX 0.13
- URGN -0.02
- Stochastic Oscillator
- TCBX 51.94
- URGN 26.40
About TCBX Third Coast Bancshares Inc.
Third Coast Bancshares Inc is a bank holding company. It focuses on providing commercial banking solutions to small and medium-sized businesses and professionals with operations in its markets. The bank operates eleven branches in the Greater Houston, Dallas-Fort Worth, and Austin-San Antonio markets, and one branch in Detroit, Texas. The company operates through one segment, community banking, It generates the majority of its revenue from interest on loans, customer service, and loan fees.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.